Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivisnebart
- Development stage
- Phase 2
- Lead developer
- Alector
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Nivisnebart is a human monoclonal antibody of the IgG1κ subtype that specifically targets sortilin (SORT1). The drug works by blocking sortilin activity, which is a protein that shuttles progranulin into cellular degradation pathways. By inhibiting sortilin, nivisnebart increases progranulin levels.[1][4] Progranulin serves as a key regulator of immune activity in the brain and is involved in neuroprotection. The drug was initially developed by Alector and is now being developed in collaboration with GSK for neurodegenerative diseases, particularly Alzheimer's disease.[4][5]
- Other names
- GSK-4527226GSK4527226GSK 4527226
02
Targets
SORT1 (Sortilin)
Beyond the preview
Go deeper on nivisnebart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivisnebart.